Skip to main content
AAPL-0.46%MSFT+0.82%NVDA+4.55%GOOGL-1.24%AMZN+0.96%SPCX+3.16%TSM-3.68%AVGO+2.46%META+0.61%TSLA+1.11%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.63%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.59%0700.HK-0.56%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.14%UNH-5.42%ORCL-3.38%3988.HK+0.04%BAC-1.28%HD-2.45%GE+0.38%0857.HK0.00%1816.HK-26.12%1288.HK-0.98%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%INTC-0.54%MS-1.10%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.87%AUDUSD-0.73%NZDJPY-0.70%GBPAUD+0.67%AUDCHF-0.59%NZDUSD-0.52%GBPNZD+0.50%AUDCAD-0.47%EURAUD+0.47%EURJPY-0.43%CADJPY-0.42%GBPTRY+0.41%NZDCHF-0.40%GBPHKD+0.32%CHFJPY-0.29%NZDCAD-0.28%GBPMXN-0.28%EURNZD+0.27%EURUSD-0.26%USDCAD+0.26%EURGBP-0.22%GBPCAD+0.21%GBPJPY-0.20%NZDMXN+0.20%AUDNZD-0.19%USDZAR+0.18%USDJPY-0.17%USDMXN+0.17%USDTRY+0.16%USDILS+0.16%GBPZAR+0.16%USDCHF+0.16%AUDSGD-0.13%CHFNOK+0.13%GBPCHF+0.13%USDPLN+0.12%EURZAR+0.12%AUDDKK-0.11%CHFSEK+0.11%CADCHF-0.11%EURCHF-0.10%CHFSGD+0.09%AUDNOK-0.09%PLNJPY-0.09%EURPLN+0.08%USDNOK+0.08%USDCNH-0.08%NZDSGD+0.07%USDTHB-0.06%EURHKD-0.06%USDDKK+0.05%USDSEK+0.05%NOKJPY-0.04%USDCOP-0.04%USDSGD+0.03%GBPUSD-0.03%EURNOK+0.03%GBPSGD+0.03%EURSGD-0.02%EURCNH-0.01%EURCZK-0.01%EURSEK0.00%EURDKK0.00%USDHKD0.00%EURCAD0.00%SGDJPY0.00%GAGUSD-2.08%XAGUSD-2.07%GAUUSD-1.19%XAUUSD-1.19%XPTUSD-1.14%USOIL-0.50%UKOIL-0.50%HG1-0.48%W1-0.43%S1+0.19%C1-0.17%XNGUSD-0.01%BTCUSD-0.94%ETHUSD+58.05%USDTUSD-0.03%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+4.80%XMRUSDT+1.59%DOGEUSD+59.04%LINKUSD+0.21%XLMUSD+1.32%BCHUSDT-0.14%LTCUSD+50.36%UNIUSD+0.83%TONUSD+63.46%SUIUSD+0.81%HBARUSDT-0.35%TAOUSDT+1.60%AAVEUSD+1.91%ONDOUSDT-0.64%ICPUSDT-9.10%DOTUSDT-0.32%WLDUSDT+0.32%ARBUSDT-0.61%INJUSDT+5.58%ATOMUSDT-1.52%STXUSDT+4.37%PYTHUSDT+0.33%TIAUSDT-1.07%FETUSDT-0.98%SEIUSDT+1.04%JUPUSDT+7.35%GRTUSDT+3.60%OPUSDT-3.62%IOTAUSDT+1.94%POLUSDT+2.78%WIFUSDT-0.31%AXSUSDT-0.21%EOSUSDT+1.55%FARTCOINUSDT-3.28%IMXUSDT+0.96%GALAUSDT-2.69%DYDXUSDT+1.31%ORDIUSDT-1.17%NOTUSDT-1.46%RONINUSDT-0.65%AAPL-0.46%MSFT+0.82%NVDA+4.55%GOOGL-1.24%AMZN+0.96%SPCX+3.16%TSM-3.68%AVGO+2.46%META+0.61%TSLA+1.11%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.63%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.59%0700.HK-0.56%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.14%UNH-5.42%ORCL-3.38%3988.HK+0.04%BAC-1.28%HD-2.45%GE+0.38%0857.HK0.00%1816.HK-26.12%1288.HK-0.98%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%INTC-0.54%MS-1.10%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.87%AUDUSD-0.73%NZDJPY-0.70%GBPAUD+0.67%AUDCHF-0.59%NZDUSD-0.52%GBPNZD+0.50%AUDCAD-0.47%EURAUD+0.47%EURJPY-0.43%CADJPY-0.42%GBPTRY+0.41%NZDCHF-0.40%GBPHKD+0.32%CHFJPY-0.29%NZDCAD-0.28%GBPMXN-0.28%EURNZD+0.27%EURUSD-0.26%USDCAD+0.26%EURGBP-0.22%GBPCAD+0.21%GBPJPY-0.20%NZDMXN+0.20%AUDNZD-0.19%USDZAR+0.18%USDJPY-0.17%USDMXN+0.17%USDTRY+0.16%USDILS+0.16%GBPZAR+0.16%USDCHF+0.16%AUDSGD-0.13%CHFNOK+0.13%GBPCHF+0.13%USDPLN+0.12%EURZAR+0.12%AUDDKK-0.11%CHFSEK+0.11%CADCHF-0.11%EURCHF-0.10%CHFSGD+0.09%AUDNOK-0.09%PLNJPY-0.09%EURPLN+0.08%USDNOK+0.08%USDCNH-0.08%NZDSGD+0.07%USDTHB-0.06%EURHKD-0.06%USDDKK+0.05%USDSEK+0.05%NOKJPY-0.04%USDCOP-0.04%USDSGD+0.03%GBPUSD-0.03%EURNOK+0.03%GBPSGD+0.03%EURSGD-0.02%EURCNH-0.01%EURCZK-0.01%EURSEK0.00%EURDKK0.00%USDHKD0.00%EURCAD0.00%SGDJPY0.00%GAGUSD-2.08%XAGUSD-2.07%GAUUSD-1.19%XAUUSD-1.19%XPTUSD-1.14%USOIL-0.50%UKOIL-0.50%HG1-0.48%W1-0.43%S1+0.19%C1-0.17%XNGUSD-0.01%BTCUSD-0.94%ETHUSD+58.05%USDTUSD-0.03%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+4.80%XMRUSDT+1.59%DOGEUSD+59.04%LINKUSD+0.21%XLMUSD+1.32%BCHUSDT-0.14%LTCUSD+50.36%UNIUSD+0.83%TONUSD+63.46%SUIUSD+0.81%HBARUSDT-0.35%TAOUSDT+1.60%AAVEUSD+1.91%ONDOUSDT-0.64%ICPUSDT-9.10%DOTUSDT-0.32%WLDUSDT+0.32%ARBUSDT-0.61%INJUSDT+5.58%ATOMUSDT-1.52%STXUSDT+4.37%PYTHUSDT+0.33%TIAUSDT-1.07%FETUSDT-0.98%SEIUSDT+1.04%JUPUSDT+7.35%GRTUSDT+3.60%OPUSDT-3.62%IOTAUSDT+1.94%POLUSDT+2.78%WIFUSDT-0.31%AXSUSDT-0.21%EOSUSDT+1.55%FARTCOINUSDT-3.28%IMXUSDT+0.96%GALAUSDT-2.69%DYDXUSDT+1.31%ORDIUSDT-1.17%NOTUSDT-1.46%RONINUSDT-0.65%

Medtronic reports strong SPYRAL AFFIRM data

NEWS

November 3, 2026 at 20:21 UTC

3 min read
Catheter-based blood pressure treatment device in hospital lab after strong SPYRAL AFFIRM trial data

Key Points

  • 01SPYRAL AFFIRM shows significant six-month blood pressure reductions
  • 02Office systolic pressure fell 18.2 mmHg from baseline
  • 03Nearly nine in ten patients experienced clinical benefit at six months
  • 04FDA approved an updated U.S. label for Symplicity Spyral

SPYRAL AFFIRM delivers significant blood pressure drops

Medtronic (MDT) announced primary six-month results from the SPYRAL AFFIRM post-approval study of its Symplicity Spyral renal denervation system, showing statistically significant and clinically meaningful blood pressure reductions compared with baseline. The findings were presented as late-breaking data at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 annual meeting and simultaneously published in Circulation Cardiovascular Interventions.

At six months, office systolic blood pressure decreased by 18.2 mmHg from baseline. Home blood pressure declined by 9.4 mmHg, while 24-hour ambulatory blood pressure fell by 9.7 mmHg. Each reduction was statistically significant, with p-values below 0.0001, indicating a consistent treatment effect across different blood pressure measurements.

Blood pressure medication use remained unchanged through six months, at an average of 3.6 medications per patient. This indicates that the observed blood pressure improvements were achieved without increasing antihypertensive drug therapy.

Clinical benefit and safety outcomes

Nearly nine out of ten patients treated with the Symplicity Spyral system experienced a clinical benefit at six months. A separate pooled analysis replicated this clinical benefit at three years, reinforcing the durability of the response in patients undergoing the procedure.

The composite safety endpoint occurred in 2.1% of patients in the study. Six-month results in the U.S. primary endpoint cohort were evaluated against a prespecified performance goal, reflecting a prospective, single-arm post-approval design rather than a randomized control comparison.

Similar blood pressure reductions were demonstrated in several key subgroups, including women, Black American and Hispanic patients, and patients aged 65 years and older. These findings suggest that the procedure’s blood pressure-lowering effects extended across a diverse treated population within the study.

FDA labeling update for Symplicity Spyral

Alongside the SPYRAL AFFIRM data, Medtronic (MDT) received FDA approval for a U.S. labeling update to the Symplicity blood pressure procedure. The update expands clinical evidence informing treatment options while leaving the device’s indication unchanged.

The revised labeling adds clinical data for patients with isolated systolic hypertension, chronic kidney disease up to stage 3b, and type 2 diabetes. Evidence from the SPYRAL HTN clinical program, including SPYRAL AFFIRM and the Global SYMPLICITY Registry DEFINE, supported this labeling change.

The combination of significant six-month blood pressure reductions, high rates of clinical benefit, stable medication use, and a low composite safety event rate provides new post-approval outcomes data for the Symplicity Spyral system. The FDA’s labeling update aligns the device’s information with the expanding clinical experience in broader hypertension populations.

Key Takeaways

  • 01SPYRAL AFFIRM showed that Symplicity Spyral can lower blood pressure meaningfully without adding more antihypertensive drugs over six months.
  • 02High clinical benefit rates and a low composite safety event rate strengthen the post-approval evidence base for Medtronic (MDT)’s renal denervation technology.
  • 03The FDA’s updated U.S. label broadens the documented evidence to important comorbid groups, including patients with type 2 diabetes and chronic kidney disease up to stage 3b.

Medtronic reports strong SPYRAL AFFIRM data | Trading Dashboard